Proteon

PRTO NASDAQ
0.4511
+0.0310
+7.37%
After Hours: 0.4450 -0.0061 -1.35% 17:56 06/18 EDT
Open
0.4259
Prev Close
0.4201
High
0.4600
Low
0.4200
Volume
846.23K
Avg Vol (3M)
1.76M
52 Week High
3.940
52 Week Low
0.3500
% Turnover
4.32%
Market Cap
8.83M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Proteon PRTO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.
MORE >

Recently

Name
Price
%Change